FDA Grants Breakthrough Therapy Designation to Plixorafenib for BRAF V600E GliomaBySabrina SeraniApril 2nd 2026
Tucatinib-Based Triple Therapy Improves Survival in HER2+ Breast Cancer LMBySabrina SeraniMarch 27th 2026